An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis

Graham Devereux; Sandra Steele; Timothy Jagelman; Shona Fielding; Robert Muirhead; Jeff Brady; Christal Grierson; Richard Brooker; John Winter; Tom Fardon; Jonathan McCormick; Jeffrey T.J. Huang; Douglas Miller

doi:10.1016/j.jcf.2014.01.010

An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis

Graham Devereux (Lead / Corresponding author), Sandra Steele, Timothy Jagelman, Shona Fielding, Robert Muirhead, Jeff Brady, Christal Grierson, Richard Brooker, John Winter, Tom Fardon, Jonathan McCormick, Jeffrey T.J. Huang, Douglas Miller

Research output: Contribution to journal › Article › peer-review

39 Citations (Scopus)

Abstract

Background: In cystic fibrosis (CF), cross-sectional studies have reported sputum matrix metalloproteinase (MMP)-9 to be elevated and negatively correlated with FEV₁. This longitudinal study examined the association between MMP-9 and tissue inhibitors of metalloproteinases (TIMPs) to prognostic parameters in CF.

Method: A cross-sectional survey of CF and control subjects; CF patients were followed up for a median of 49. months. MMP-9 and TIMP-1 and TIMP-2 were quantified in sputum and plasma.

Results: Seventy-three patients with CF, median age 22 years, and 40 controls were recruited. Fifty-three of these CF patients were followed up. Prospectively, in CF subjects, plasma MMP-9 activity was adversely associated with FEV₁ (β -1.15 (95% CI -2.10, -0.20), p=0.019) and rate of FEV₁ decline, and plasma TIMP-1 was adversely associated with mortality: hazard ratio 3.66 (1.91-7.04), p<0.001.

Conclusions: These associations further justify investigation of MMP-9 and TIMP-1 as biomarkers for short- to medium-term FEV₁ decline and mortality in patients with CF.

Original language	English
Pages (from-to)	557-563
Number of pages	7
Journal	Journal of Cystic Fibrosis
Volume	13
Issue number	5
Early online date	11 Feb 2014
DOIs	https://doi.org/10.1016/j.jcf.2014.01.010
Publication status	Published - Sept 2014

Keywords

Cystic fibrosis
FEV
MMP-9
Mortality
TIMP-1

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Pediatrics, Perinatology, and Child Health

Access to Document

10.1016/j.jcf.2014.01.010

Cite this

@article{3f6a7d02e1364e3284c23214b8803707,

title = "An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis",

abstract = "Background: In cystic fibrosis (CF), cross-sectional studies have reported sputum matrix metalloproteinase (MMP)-9 to be elevated and negatively correlated with FEV1. This longitudinal study examined the association between MMP-9 and tissue inhibitors of metalloproteinases (TIMPs) to prognostic parameters in CF. Method: A cross-sectional survey of CF and control subjects; CF patients were followed up for a median of 49. months. MMP-9 and TIMP-1 and TIMP-2 were quantified in sputum and plasma. Results: Seventy-three patients with CF, median age 22 years, and 40 controls were recruited. Fifty-three of these CF patients were followed up. Prospectively, in CF subjects, plasma MMP-9 activity was adversely associated with FEV1 (β -1.15 (95% CI -2.10, -0.20), p=0.019) and rate of FEV1 decline, and plasma TIMP-1 was adversely associated with mortality: hazard ratio 3.66 (1.91-7.04), p<0.001. Conclusions: These associations further justify investigation of MMP-9 and TIMP-1 as biomarkers for short- to medium-term FEV1 decline and mortality in patients with CF.",

keywords = "Cystic fibrosis, FEV, MMP-9, Mortality, TIMP-1",

author = "Graham Devereux and Sandra Steele and Timothy Jagelman and Shona Fielding and Robert Muirhead and Jeff Brady and Christal Grierson and Richard Brooker and John Winter and Tom Fardon and Jonathan McCormick and Huang, {Jeffrey T.J.} and Douglas Miller",

year = "2014",

month = sep,

doi = "10.1016/j.jcf.2014.01.010",

language = "English",

volume = "13",

pages = "557--563",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis

AU - Devereux, Graham

AU - Steele, Sandra

AU - Jagelman, Timothy

AU - Fielding, Shona

AU - Muirhead, Robert

AU - Brady, Jeff

AU - Grierson, Christal

AU - Brooker, Richard

AU - Winter, John

AU - Fardon, Tom

AU - McCormick, Jonathan

AU - Huang, Jeffrey T.J.

AU - Miller, Douglas

PY - 2014/9

Y1 - 2014/9

N2 - Background: In cystic fibrosis (CF), cross-sectional studies have reported sputum matrix metalloproteinase (MMP)-9 to be elevated and negatively correlated with FEV1. This longitudinal study examined the association between MMP-9 and tissue inhibitors of metalloproteinases (TIMPs) to prognostic parameters in CF. Method: A cross-sectional survey of CF and control subjects; CF patients were followed up for a median of 49. months. MMP-9 and TIMP-1 and TIMP-2 were quantified in sputum and plasma. Results: Seventy-three patients with CF, median age 22 years, and 40 controls were recruited. Fifty-three of these CF patients were followed up. Prospectively, in CF subjects, plasma MMP-9 activity was adversely associated with FEV1 (β -1.15 (95% CI -2.10, -0.20), p=0.019) and rate of FEV1 decline, and plasma TIMP-1 was adversely associated with mortality: hazard ratio 3.66 (1.91-7.04), p<0.001. Conclusions: These associations further justify investigation of MMP-9 and TIMP-1 as biomarkers for short- to medium-term FEV1 decline and mortality in patients with CF.

AB - Background: In cystic fibrosis (CF), cross-sectional studies have reported sputum matrix metalloproteinase (MMP)-9 to be elevated and negatively correlated with FEV1. This longitudinal study examined the association between MMP-9 and tissue inhibitors of metalloproteinases (TIMPs) to prognostic parameters in CF. Method: A cross-sectional survey of CF and control subjects; CF patients were followed up for a median of 49. months. MMP-9 and TIMP-1 and TIMP-2 were quantified in sputum and plasma. Results: Seventy-three patients with CF, median age 22 years, and 40 controls were recruited. Fifty-three of these CF patients were followed up. Prospectively, in CF subjects, plasma MMP-9 activity was adversely associated with FEV1 (β -1.15 (95% CI -2.10, -0.20), p=0.019) and rate of FEV1 decline, and plasma TIMP-1 was adversely associated with mortality: hazard ratio 3.66 (1.91-7.04), p<0.001. Conclusions: These associations further justify investigation of MMP-9 and TIMP-1 as biomarkers for short- to medium-term FEV1 decline and mortality in patients with CF.

KW - Cystic fibrosis

KW - FEV

KW - MMP-9

KW - Mortality

KW - TIMP-1

U2 - 10.1016/j.jcf.2014.01.010

DO - 10.1016/j.jcf.2014.01.010

M3 - Article

C2 - 24525080

AN - SCOPUS:84926134611

SN - 1569-1993

VL - 13

SP - 557

EP - 563

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - 5

ER -

An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this